Effect of Dexmedetomidine vs Esmolol or Placebo on Cerebral Hemodynamics in Septic Shock

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2023

Conditions
Septic ShockStress ResponseCerebral Hemodynamics
Interventions
DRUG

Dexmedetomidine Hydrochloride

The continuous intravenous infusion of dexmedetomidine (0.1mg/ml) will start at 0.1ug/kg/h, increasing every 20 minutes by a step change of 0.05-0.2ug/kg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stopped if the heart rate fall below 80b.p.m..

DRUG

Esmolol Hydrochloride

The continuous intravenous infusion of esmolol (10mg/ml) will start at 20mg/h, increasing every 20 minutes by a step change of 20mg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stop if the heart rate fall below 80b.p.m..

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing

All Listed Sponsors
collaborator

Tibet Autonomous Region People's Hospital

OTHER

lead

Xinchen Wang

OTHER

NCT06169475 - Effect of Dexmedetomidine vs Esmolol or Placebo on Cerebral Hemodynamics in Septic Shock | Biotech Hunter | Biotech Hunter